跳至主要内容
临床试验/NL-OMON28713
NL-OMON28713招募中不适用

A Double Blind, Randomized, Placebo Controlled,Multi-Center Trial of Anti-TNF¨¢Chimeric Monoclonal Antibody (Infliximab, Remicade®)in Combination with Methotrexate in Patients withVery Early Inflammatory Arthritis.

Josef S. Smolen MDDepartment of RheumatologyMedical University of ViennaWaehringer Guertel 18-20A-1090 Vienna, Austria+43-1-40400-4300josef.smolen@wienkav.at0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Men and women, >= 18 and <= 75 years of age, capable of understanding and signing an informed consent;
  • 2. The presence of arthritis:

排除标准

  • 1. Have arthritis with a distinct diagnosis, made after a routine diagnostic work-up
  • (examples are SLE, psoriatic arthritis, systemic sclerosis, gout, pseudogout, Lyme
  • arthritis, reactive arthritis, Parvo viral arthritis);

研究者

发起方
Josef S. Smolen MDDepartment of RheumatologyMedical University of ViennaWaehringer Guertel 18-20A-1090 Vienna, Austria+43-1-40400-4300josef.smolen@wienkav.at

相似试验